Lyell and Pact partner on T-cell therapy

By The Science Advisory Board staff writers

June 18, 2020 -- Lyell Immunopharma and Pact Pharma have formed a strategic partnership to jointly develop and test a next-generation personalized anticancer T-cell therapy against solid tumors.

The companies will develop personalized T-cell therapy using the patient's own T cells through nonviral precision genome engineering for tumor neoantigen specificity. This therapy aims to overcome potential tumor resistance and T-cell exhaustion.

Pact will receive upfront and milestone payments from the partnership. If successful, the drug development program will be jointly owned and each company will share profits equally.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.